Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance

Drug Resistance Updates

Volumn 13, Issue 4-5, 2010, Pages 119-131

  Engelmann, David ^a   Pützer, Brigitte M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Apoptosis signalling; Cancer; Chemoresistance; DNA damage response; E2F transcription factor

Indexed keywords

DNA; PROTEIN P53; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; DNA DAMAGE; DRUG MECHANISM; GENOTOXICITY; HUMAN; INTRACELLULAR SIGNALING; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; HUMANS; NEOPLASMS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77957931294     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.06.001     Document Type: Article

References (171)

1. Abraham H., Somogyvari-Vigh A., Maderdrut J.L., Vigh S., Arimura A. Filament size influences temperature changes and brain damage following middle cerebral artery occlusion in rats. Exp. Brain Res. 2002, 142:131-138.
2. Agger K., Santoni-Rugiu E., Holmberg C., Karlstrom O., Helin K. Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS. Oncogene 2005, 24:780-789.
3. Alla V., Engelmann D., Niemetz A., Pahnke J., Schmidt A., Kunz M., Emmrich S., Steder M., Koczan D., Pützer B.M. E2F1 in melanoma progression and metastasis. J. Natl. Cancer Inst. 2010, 102:127-133.
4. Ambrosini G., Sambol E.B., Carvajal D., Vassilev L.T., Singer S., Schwartz G.K. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007, 26:3473-3481.
5. Banerjee D., Gorlick R., Liefshitz A., Danenberg K., Danenberg P.C., Danenberg P.V., Klimstra D., Jhanwar S., Cordon-Cardo C., Fong Y., Kemeny N., Bertino J.R. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 2000, 60:2365-2367.
6. Banerjee D., Schnieders B., Fu J.Z., Adhikari D., Zhao S.C., Bertino J.R. Role of E2F-1 in chemosensitivity. Cancer Res. 1998, 58:4292-4296.
7. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
8. Bates S., Phillips A.C., Clark P.A., Stott F., Peters G., Ludwig R.L., Vousden K.H. p14ARF links the tumour suppressors RB and p53. Nature 1998, 395:124-125.
9. Belvedere O., Puglisi F., Di Loreto C., Cataldi P., Guglielmi A., Aschele C., Sobrero A. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann. Oncol. 2004, 15:55-58.
10. Ben Shachar B., Feldstein O., Hacohen D., Ginsberg D. The Tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Mol. Cancer Res. 2010, 8:363-372.
11. Berkovich E., Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene 2003, 22:161-167.
12. Blattner C., Sparks A., Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 1999, 19:3704-3713.
13. Britschgi A., Trinh E., Rizzi M., Jenal M., Ress A., Tobler A., Fey M.F., Helin K., Tschan M.P. DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene 2008, 27:5706-5716.
14. Canman C.E., Lim D.S. The role of ATM in DNA damage responses and cancer. Oncogene 1998, 17:3301-3308.
15. Cao Q., Xia Y., Azadniv M., Crispe I.N. The E2F-1 transcription factor promotes caspase-8 and bid expression, and enhances Fas signaling in T cells. J. Immunol. 2004, 173:1111-1117.
16. Carcagno A.L., Ogara M.F., Sonzogni S.V., Marazita M.C., Sirkin P.F., Ceruti J.M., Canepa E.T. E2F1 transcription is induced by genotoxic stress through ATM/ATR activation. IUBMB Life 2009, 61:537-543.
17. Cassimere E.K., Pyndiah S., Sakamuro D. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ. 2009, 16:1641-1653.
18. Chaussepied M., Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol. Cell 2004, 16:831-837.
19. Chen D., Pacal M., Wenzel P., Knoepfler P.S., Leone G., Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature 2009, 462:925-929.
20. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
21. Chen P.L., Riley D.J., Chen Y., Lee W.H. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 1996, 10:2794-2804.
22. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448.
23. Chong J.L., Wenzel P.L., Saenz-Robles M.T., Nair V., Ferrey A., Hagan J.P., Gomez Y.M., Sharma N., Chen H.Z., Ouseph M., Wang S.H., Trikha P., Culp B., Mezache L., Winton D.J., Sansom O.J., Chen D., Bremner R., Cantalupo P.G., Robinson M.L., Pipas J.M., Leone G. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009, 462:930-934.
24. Cole M.D., Cowling V.H. Specific regulation of mRNA cap methylation by the c-Myc and E2F1 transcription factors. Oncogene 2009, 28:1169-1175.
25. Crawford N.P., Qian X., Ziogas A., Papageorge A.G., Boersma B.J., Walker R.C., Lukes L., Rowe W.L., Zhang J., Ambs S., Lowy D.R., Anton-Culver H., Hunter K.W. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet. 2007, 3:e214.
26. Croxton R., Ma Y., Song L., Haura E.B., Cress W.D. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002, 21:1359-1369.
27. Dai J.M., Wang Z.Y., Sun D.C., Lin R.X., Wang S.Q. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J. Cell. Physiol. 2007, 210:161-166.
28. DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim. Biophys. Acta 2002, 1602:131-150.
29. Dick F.A., Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol. Cell 2003, 12:639-649.
30. Dijkers P.F., Medema R.H., Lammers J.W., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 2000, 10:1201-1204.
31. Dong Y.B., Yang H.L., Elliott M.J., Liu T.J., Stilwell A., Atienza C., McMasters K.M. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 1999, 86:2021-2033.
32. Dong Y.B., Yang H.L., Elliott M.J., McMasters K.M. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 2002, 62:1776-1783.
33. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
34. Eischen C.M., Packham G., Nip J., Fee B.E., Hiebert S.W., Zambetti G.P., Cleveland J.L. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 2001, 20:6983-6993.
35. Elliott M.J., Baker J.D., Dong Y.B., Yang H.L., Gleason J.F., McMasters K.M. Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer. Tumour Biol. 2002, 23:324-336.
36. Elliott M.J., Farmer M.R., Atienza C., Stilwell A., Dong Y.B., Yang H.L., Wong S.L., McMasters K.M. E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol. 2002, 23:76-86.
37. Emmrich S., Pützer B.M. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle 2010, 9:2555-2567.
38. Engelmann D., Knoll S., Ewerth D., Steder M., Stoll A., Putzer B.M. Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cell. Mol. Life Sci. 2010, 67:931-948.
39. Eymin B., Gazzeri S., Brambilla C., Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001, 20:1678-1687.
40. Field S.J., Tsai F.Y., Kuo F., Zubiaga A.M., Kaelin W.G., Livingston D.M., Orkin S.H., Greenberg M.E. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996, 85:549-561.
41. Fortin A., MacLaurin J.G., Arbour N., Cregan S.P., Kushwaha N., Callaghan S.M., Park D.S., Albert P.R., Slack R.S. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. J. Biol. Chem. 2004, 279:28706-28714.
42. Freeman S.N., Ma Y., Cress W.D. RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J. Biol. Chem. 2008, 283:2353-2362.
43. Fueyo J., Gomez-Manzano C., Yung W.K., Liu T.J., Alemany R., McDonnell T.J., Shi X., Rao J.S., Levin V.A., Kyritsis A.P. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 1998, 4:685-690.
44. Furukawa Y., Nishimura N., Furukawa Y., Satoh M., Endo H., Iwase S., Yamada H., Matsuda M., Kano Y., Nakamura M. Apaf-1 is a mediator of E2F-1-induced apoptosis. J. Biol. Chem. 2002, 277:39760-39768.
45. Galbiati L., Mendoza-Maldonado R., Gutierrez M.I., Giacca M. Regulation of E2F-1 after DNA damage by p300-mediated acetylation and ubiquitination. Cell Cycle 2005, 4:930-939.
46. Gomez-Manzano C., Lemoine M.G., Hu M., He J., Mitlianga P., Liu T.J., Yung A.W., Fueyo J., Groves M.D. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int. J. Oncol. 2001, 19:359-365.
47. Gomez-Manzano C., Mitlianga P., Fueyo J., Lee H.Y., Hu M., Spurgers K.B., Glass T.L., Koul D., Liu T.J., McDonnell T.J., Yung W.K. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res. 2001, 61:6693-6697.
48. Gorgoulis V.G., Zacharatos P., Mariatos G., Kotsinas A., Bouda M., Kletsas D., Asimacopoulos P.J., Agnantis N., Kittas C., Papavassiliou A.G. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J. Pathol. 2002, 198:142-156.
49. Gudi R., Barkinge J., Hawkins S., Prabhakar B., Kanteti P. Siva-1 promotes K-48 polyubiquitination of TRAF2 and inhibits TCR-mediated activation of NF-kappaB. J. Environ. Pathol. Toxicol. Oncol. 2009, 28:25-38.
50. Hallstrom T.C., Mori S., Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008, 13:11-22.
51. Hallstrom T.C., Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10848-10853.
52. Han S., Park K., Bae B.N., Kim K.H., Kim H.J., Kim Y.D., Kim H.Y. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res. Treat. 2003, 82:11-16.
53. Hatai T., Matsuzawa A., Inoshita S., Mochida Y., Kuroda T., Sakamaki K., Kuida K., Yonehara S., Ichijo H., Takeda K. Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J. Biol. Chem. 2000, 275:26576-26581.
54. Helgason G.V., O'Prey J., Ryan K.M. Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res. 2010, 70:4074-4080.
55. Hershko T., Chaussepied M., Oren M., Ginsberg D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ. 2005, 12:377-383.
56. Hershko T., Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 2004, 279:8627-8634.
57. Hershko T., Korotayev K., Polager S., Ginsberg D. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J. Biol. Chem. 2006, 281:31309-31316.
58. Hiebert S.W., Packham G., Strom D.K., Haffner R., Oren M., Zambetti G., Cleveland J.L. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell. Biol. 1995, 15:6864-6874.
59. Hofferer M., Wirbelauer C., Humar B., Krek W. Increased levels of E2F-1-dependent DNA binding activity after UV- or gamma-irradiation. Nucleic Acids Res. 1999, 27:491-495.
60. Holmberg C., Helin K., Sehested M., Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 1998, 17:143-155.
61. Hsieh J.K., Fredersdorf S., Kouzarides T., Martin K., Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 1997, 11:1840-1852.
62. Hsieh J.K., Yap D., O'Connor D.J., Fogal V., Fallis L., Chan F., Zhong S., Lu X. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell. Biol. 2002, 22:78-93.
63. Huang Y., Ishiko T., Nakada S., Utsugisawa T., Kato T., Yuan Z.M. Role for E2F in DNA damage-induced entry of cells into S phase. Cancer Res. 1997, 57:3640-3643.
64. Hunt K.K., Deng J., Liu T.J., Wilson-Heiner M., Swisher S.G., Clayman G., Hung M.C. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997, 57:4722-4726.
65. Ianari A., Gallo R., Palma M., Alesse E., Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J. Biol. Chem. 2004, 279:30830-30835.
66. Ianari A., Natale T., Calo E., Ferretti E., Alesse E., Screpanti I., Haigis K., Gulino A., Lees J.A. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009, 15:184-194.
67. Inoue Y., Kitagawa M., Taya Y. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J. 2007, 26:2083-2093.
68. Irwin M., Marin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., Kaelin W.G. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000, 407:645-648.
69. Iwamoto M., Banerjee D., Menon L.G., Jurkiewicz A., Rao P.H., Kemeny N.E., Fong Y., Jhanwar S.C., Gorlick R., Bertino J.R. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol. Ther. 2004, 3:395-399.
70. Jenal M., Trinh E., Britschgi C., Britschgi A., Roh V., Vorburger S.A., Tobler A., Leprince D., Fey M.F., Helin K., Tschan M.P. The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1. Mol. Cancer Res. 2009, 7:916-922.
71. Jin W., Di G., Li J., Chen Y., Li W., Wu J., Cheng T., Yao M., Shao Z. TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS Lett. 2007, 581:3826-3832.
72. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
73. Kherrouche Z., Blais A., Ferreira E., De Launoit Y., Monte D. ASK-1 (apoptosis signal-regulating kinase 1) is a direct E2F target gene. Biochem. J. 2006, 396:547-556.
74. Kitagawa M., Aonuma M., Lee S.H., Fukutake S., McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008, 27:5303-5314.
75. Kuhn H., Liebers U., Gessner C., Schumacher A., Witt C., Schauer J., Kovesdi I., Wolff G. Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis. Eur. Respir. J. 2002, 20:703-709.
76. Kwon M.J., Nam E.S., Cho S.J., Park H.R., Shin H.S., Park J.H., Park C.H., Lee W.J. E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma. Ann. Surg. Oncol. 2010, 17:564-571.
77. Lazzerini Denchi E., Helin K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep. 2005, 6:661-668.
78. Lee J.S., Leem S.H., Lee S.Y., Kim S.C., Park E.S., Kim S.B., Kim S.K., Kim Y.J., Kim W.J., Chu I.S. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 2010, 28:2660-2667.
79. Lee J., Park C.K., Park J.O., Lim T., Park Y.S., Lim H.Y., Lee I., Sohn T.S., Noh J.H., Heo J.S., Kim S., Lim do H., Kim K.M., Kang W.K. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin. Cancer Res. 2008, 14:82-88.
80. Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V. Down-regulation of death-associated protein kinase-2 is required for beta-catenin-induced anoikis resistance of malignant epithelial cells. J. Biol. Chem. 2009, 284:2012-2022.
81. Li J., Ran C., Li E., Gordon F., Comstock G., Siddiqui H., Cleghorn W., Chen H.Z., Kornacker K., Liu C.G., Pandit S.K., Khanizadeh M., Weinstein M., Leone G., de Bruin A. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev. Cell 2008, 14:62-75.
82. Li Z., Kreutzer M., Mikkat S., Mise N., Glocker M.O., Putzer B.M. Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death. Proteomics 2006, 6:5735-5745.
83. Lin S.Y., Rai R., Li K., Xu Z.X., Elledge S.J. BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15105-15109.
84. Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001, 15:1833-1844.
85. Liu D., Wei Y., Zhou F., Ge Y., Xu J., Chen H., Zhang W., Yun X., Jiang J. E1AF promotes mithramycin A-induced Huh-7 cell apoptosis depending on its DNA-binding domain. Arch. Biochem. Biophys. 2008, 477:20-26.
86. Liu K., Luo Y., Lin F.T., Lin W.C. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004, 18:673-686.
87. Liu K., Paik J.C., Wang B., Lin F.T., Lin W.C. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J. 2006, 25:4795-4807.
88. Liu T.J., Wang M., Breau R.L., Henderson Y., El-Naggar A.K., Steck K.D., Sicard M.W., Clayman G.L. Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. Cancer Gene Ther. 1999, 6:163-171.
89. Lize M., Pilarski S., Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2010, 17:452-458.
90. Louie M.C., McClellan A., Siewit C., Kawabata L. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol. Cancer Res. 2010, 8:343-352.
91. Marabese M., Vikhanskaya F., Rainelli C., Sakai T., Broggini M. DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res. 2003, 31:6624-6632.
92. Markham D., Munro S., Soloway J., O'Connor D.P., La Thangue N.B. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep. 2006, 7:192-198.
93. Martinez L.A., Goluszko E., Chen H.Z., Leone G., Post S., Lozano G., Chen Z., Chauchereau A. E2F3 is a mediator of DNA damage-induced apoptosis. Mol. Cell. Biol. 2010, 30:524-536.
94. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updates 2008, 11:164-179.
95. Meng R.D., Phillips P., El-Deiry W.S. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int. J. Oncol. 1999, 14:5-14.
96. Merdzhanova G., Edmond V., De Seranno S., Van den Broeck A., Corcos L., Brambilla C., Brambilla E., Gazzeri S., Eymin B. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 2008, 15:1815-1823.
97. Milton A.H., Khaire N., Ingram L., O'Donnell A.J., La Thangue N.B. 14-3-3 proteins integrate E2F activity with the DNA damage response. EMBO J. 2006, 25:1046-1057.
98. Miyake H., Hara I., Arakawa S., Kamidono S. Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J. Cell. Biochem. 2000, 77:396-408.
99. Moon N.S., Di Stefano L., Dyson N. A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol. Cell. Biol. 2006, 26:7601-7615.
100. Moon N.S., Dyson N. E2F7 and E2F8 keep the E2F family in balance. Dev. Cell 2008, 14:1-3.
101. Moon N.S., Frolov M.V., Kwon E.J., Di Stefano L., Dimova D.K., Morris E.J., Taylor-Harding B., White K., Dyson N.J. Drosophila E2F1 has context-specific pro- and antiapoptotic properties during development. Dev. Cell 2005, 9:463-475.
102. Morris E.J., Michaud W.A., Ji J.Y., Moon N.S., Rocco J.W., Dyson N.J. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet. 2006, 2:e196.
103. Nahle Z., Polakoff J., Davuluri R.V., McCurrach M.E., Jacobson M.D., Narita M., Zhang M.Q., Lazebnik Y., Bar-Sagi D., Lowe S.W. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 2002, 4:859-864.
104. Nguyen K.H., Hachem P., Khor L.Y., Salem N., Hunt K.K., Calkins P.R., Pollack A. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:238-246.
105. Nip J., Strom D.K., Fee B.E., Zambetti G., Cleveland J.L., Hiebert S.W. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell. Biol. 1997, 17:1049-1056.
106. Nowak K., Killmer K., Gessner C., Lutz W. E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim. Biophys. Acta 2007, 1769:244-252.
107. Obexer P., Geiger K., Ambros P.F., Meister B., Ausserlechner M.J. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ. 2007, 14:534-547.
108. Obexer P., Hagenbuchner J., Unterkircher T., Sachsenmaier N., Seifarth C., Bock G., Porto V., Geiger K., Ausserlechner M. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol. Biol. Cell 2009, 20:2041-2048.
109. Osborn A.J., Elledge S.J., Zou L. Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol. 2002, 12:509-516.
110. Paik J.C., Wang B., Liu K., Lue J.K., Lin W.C. Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B. J. Biol. Chem. 2010, 285:6348-6363.
111. Parr M.J., Manome Y., Tanaka T., Wen P., Kufe D.W., Kaelin W.G., Fine H.A. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 1997, 3:1145-1149.
112. Pediconi N., Guerrieri F., Vossio S., Bruno T., Belloni L., Schinzari V., Scisciani C., Fanciulli M., Levrero M. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol. Cell. Biol. 2009, 29:1989-1998.
113. Pediconi N., Ianari A., Costanzo A., Belloni L., Gallo R., Cimino L., Porcellini A., Screpanti I., Balsano C., Alesse E., Gulino A., Levrero M. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol. 2003, 5:552-558.
114. Phillips A.C., Bates S., Ryan K.M., Helin K., Vousden K.H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 1997, 11:1853-1863.
115. Phillips A.C., Ernst M.K., Bates S., Rice N.R., Vousden K.H. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol. Cell 1999, 4:771-781.
116. Pierce A.M., Schneider-Broussard R., Gimenez-Conti I.B., Russell J.L., Conti C.J., Johnson D.G. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol. 1999, 19:6408-6414.
117. Polager S., Ginsberg D. E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress. J. Biol. Chem. 2003, 278:1443-1449.
118. Polager S., Ginsberg D. p53 and E2f: partners in life and death. Nat. Rev. Cancer 2009, 9:738-748.
119. Powers J.T., Hong S., Mayhew C.N., Rogers P.M., Knudsen E.S., Johnson D.G. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol. Cancer Res. 2004, 2:203-214.
120. Prendergast G.C., Muller A.J., Ramalingam A., Chang M.Y. BAR the door: cancer suppression by amphiphysin-like genes. Biochim. Biophys. Acta 2009, 1795:25-36.
121. Pruschy M., Wirbelauer C., Glanzmann C., Bodis S., Krek W. E2F-1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53. Cell Growth Differ. 1999, 10:141-146.
122. Qiao L., Wong B.C. Targeting apoptosis as an approach to gastrointestinal cancer therapy. Drug Resist. Updates 2009, 12:55-64.
123. Qin X.Q., Livingston D.M., Kaelin W.G., Adams P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:10918-10922.
124. Racek T., Buhlmann S., Rust F., Knoll S., Alla V., Putzer B.M. Transcriptional repression of the prosurvival endoplasmic reticulum chaperone GRP78/BIP by E2F1. J. Biol. Chem. 2008, 283:34305-34314.
125. Rai R., Dai H., Multani A.S., Li K., Chin K., Gray J., Lahad J.P., Liang J., Mills G.B., Meric-Bernstam F., Lin S.Y. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 2006, 10:145-157.
126. Real P.J., Sanz C., Gutierrez O., Pipaon C., Zubiaga A.M., Fernandez-Luna J.L. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett. 2006, 580:5905-5909.
127. Real S., Espada L., Espinet C., Santidrian A.F., Tauler A. Study of the in vivo phosphorylation of E2F1 on Ser403. Biochim. Biophys. Acta 2010, 1803:912-918.
128. Ribeiro A., Bronk S.F., Roberts P.J., Urrutia R., Gores G.J. The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology 1999, 30:1490-1497.
129. Rödicker F., Stiewe T., Zimmermann S., Putzer B.M. Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res. 2001, 61:7052-7055.
130. Rodriguez J.M., Glozak M.A., Ma Y., Cress W.D. Bok, Bcl-2-related ovarian killer, is cell cycle-regulated and sensitizes to stress-induced apoptosis. J. Biol. Chem. 2006, 281:22729-22735.
131. Rogoff H.A., Pickering M.T., Debatis M.E., Jones S., Kowalik T.F. E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol. Cell. Biol. 2002, 22:5308-5318.
132. Salon C., Merdzhanova G., Brambilla C., Brambilla E., Gazzeri S., Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007, 26:6927-6936.
133. Shan B., Lee W.H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 1994, 14:8166-8173.
134. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev. 2001, 11:71-77.
135. Stanelle J., Pützer B.M. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol. Med. 2006, 12:177-185.
136. Stanelle J., Stiewe T., Theseling C.C., Peter M., Pützer B.M. Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 2002, 30:1859-1869.
137. Stevens C., Smith L., La Thangue N.B. Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 2003, 5:401-409.
138. Stiewe T., Pützer B.M. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 2000, 26:464-469.
139. Tanaka H., Matsumura I., Ezoe S., Satoh Y., Sakamaki T., Albanese C., Machii T., Pestell R.G., Kanakura Y. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 2002, 9:1017-1029.
140. Timchenko N.A., Wilde M., Darlington G.J. C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Mol. Cell. Biol. 1999, 19:2936-2945.
141. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3:11-20.
142. Tsai K.Y., Hu Y., Macleod K.F., Crowley D., Yamasaki L., Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell 1998, 2:293-304.
143. Tyagi S., Chabes A.L., Wysocka J., Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell 2007, 27:107-119.
144. Tyagi S., Herr W. E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases. EMBO J. 2009, 28:3185-3195.
145. Urist M., Tanaka T., Poyurovsky M.V., Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004, 18:3041-3054.
146. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
147. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
148. Vilgelm A., El-Rifai W., Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist. Updates 2008, 11:152-163.
149. Wang B., Liu K., Lin F.T., Lin W.C. A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis. J. Biol. Chem. 2004, 279:54140-54152.
150. Wang C., Chen L., Hou X., Li Z., Kabra N., Ma Y., Nemoto S., Finkel T., Gu W., Cress W.D., Chen J. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat. Cell Biol. 2006, 8:1025-1031.
151. Wang C., Rauscher F.J., Cress W.D., Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. J. Biol. Chem. 2007, 282:29902-29909.
152. Wang J., Shen W.H., Jin Y.J., Brandt-Rauf P.W., Yin Y. A molecular link between E2F-1 and the MAPK cascade. J. Biol. Chem. 2007, 282:18521-18531.
153. Wang J., Yin D.P., Liu Y.X., Baer R., Yin Y. Dual specificity phosphatase 1/CL100 is a direct transcriptional target of E2F-1 in the apoptotic response to oxidative stress. Cancer Res. 2007, 67:6737-6744.
154. Wang X.P., Liu G.Z., Song A.L., Chen R.F., Li H.Y., Liu Y. Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J. Gastroenterol. 2005, 11:429-432.
155. Wei Y., Liu D., Ge Y., Zhou F., Xu J., Chen H., Gu J., Jiang J. Identification of E1AF as a target gene of E2F1-induced apoptosis in response to DNA damage. J. Biochem. 2008, 144:539-546.
156. Wikonkal N.M., Remenyik E., Knezevic D., Zhang W., Liu M., Zhao H., Berton T.R., Johnson D.G., Brash D.E. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat. Cell Biol. 2003, 5:655-660.
157. Wu J., Jin Y.J., Calaf G.M., Huang W.L., Yin Y. PAC1 is a direct transcription target of E2F-1 in apoptotic signaling. Oncogene 2007, 26:6526-6535.
158. Wu Z.L., Zheng S.S., Li Z.M., Qiao Y.Y., Aau M.Y., Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ. 2010, 17:801-810.
159. Xie W., Jiang P., Miao L., Zhao Y., Zhimin Z., Qing L., Zhu W.G., Wu M. Novel link between E2F1 and Smac/DIABLO: proapoptotic Smac/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res. 2006, 34:2046-2055.
160. Xu X., Lee J., Stern D.F. Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J. Biol. Chem. 2004, 279:34091-34094.
161. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996, 85:537-548.
162. Yamazaki K., Yajima T., Nagao T., Shinkawa H., Kondo F., Hanami K., Asoh A., Sugano I., Ishida Y. Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol. Res. Pract. 2003, 199:23-28.
163. Yang H.L., Dong Y.B., Elliott M.J., Liu T.J., Atienza C., Stilwell A., McMasters K.M. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin. Cancer Res. 1999, 5:2242-2250.
164. Yang H.L., Dong Y.B., Elliott M.J., Wong S.L., McMasters K.M. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells. Cancer Gene Ther. 2001, 8:241-251.
165. Yang S.Z., Lin F.T., Lin W.C. MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008, 9:907-915.
166. Yang X., Feng M., Jiang X., Wu Z., Li Z., Aau M., Yu Q. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009, 23:2388-2393.
167. You H., Pellegrini M., Tsuchihara K., Yamamoto K., Hacker G., Erlacher M., Villunger A., Mak T.W. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 2006, 203:1657-1663.
168. You H., Yamamoto K., Mak T.W. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9051-9056.
169. Zalmas L.P., Zhao X., Graham A.L., Fisher R., Reilly C., Coutts A.S., La Thangue N.B. DNA-damage response control of E2F7 and E2F8. EMBO Rep. 2008, 9:252-259.
170. Zhang L., Ming L., Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist. Updates 2007, 10:207-217.
171. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.